Furthermore, the anti-CTLA-4 mAb has been previously reported to exert marked therapeutic effects against various cancers and worm infections, but causes obvious body damage, i.e., immune-related adverse events, including colitis, hepatitis, and pneumonitis (37). Here, CTLA4 is linked to pneumonitis.